Usona Institute

Recent papers from Usona Institute

1. Peak Fiction: XRPD and the Illusion of NoveltyACS Medicinal Chemistry Letters · 2026
2. Proliferative Effects of the Psychedelic N,N -Dimethyltryptamine (DMT) in Human Neural Stem CellsACS Chemical Neuroscience · 2026
3. Fabricated Ancestrality: The Sonoran Desert Toad, Psychedelic Globalization, and the Ecological Politics of 5-MeO-DMTPsychedelics · 2026
4. Synthesis and Characterization of Psilocybin Metabolites and Deuterated AnalogsACS Chemical Neuroscience · 2026
5. Catalytic Strategies in Oncology and Autoimmunity: From EGFR Resistance to RNA-Guided ScreeningACS Medicinal Chemistry Letters · 2025
6. Multidimensional Strategies in Oncology: From Macrocyclic Kinase Inhibitors to Physicochemical and Transcriptomic DiagnosticsACS Medicinal Chemistry Letters · 2025
7. Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine–DMT FormulationsACS Medicinal Chemistry Letters · 2025
8. Next-Generation ADC Design and Innate Immune Modulation: Emerging Strategies for Potent Cancer Therapy and Systemic Disease ToleranceACS Medicinal Chemistry Letters · 2025
9. Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondentsPsychedelics · 2025
10. Dual Innovations in EGFR Degradation and Antigen-Specific Modulation for Multiple SclerosisACS Medicinal Chemistry Letters · 2025
11. Targeted Degradation of EGFR and PKC Isoforms: Emerging Bifunctional and Peptidic Modalities in Oncology and Immune RegulationACS Medicinal Chemistry Letters · 2025
12. Dual-State KRAS G12C Inhibitors as Emerging Therapeutics for Brain and Lung MetastasesACS Medicinal Chemistry Letters · 2025
13. Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional ValenceJournal of Psychoactive Drugs · 2025
14. Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic CotherapyACS Medicinal Chemistry Letters · 2025
15. Broadening Degrader Therapeutics: Keap1 PROTACs, Antimalarial Hybrids, and PLK1 Inhibition of NLRP3 InflammasomesACS Medicinal Chemistry Letters · 2025
16. LRRK2 Degraders for Parkinson’s Disease and Inflammation: Tau and α-Synuclein Degraders for NeurodegenerationACS Medicinal Chemistry Letters · 2025
17. Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory InnovationsACS Medicinal Chemistry Letters · 2025
18. Synthesis of Psilocin, Psilocybin and 5‐MeO‐DMT Succinate, All Labelled With Carbon‐14 at the Indole 2‐PositionJournal of Labelled Compounds and Radiopharmaceuticals · 2025
19. Tricyclic and Novel Chemotypes as Selective WRN Helicase Inhibitors for MSI-H Cancer TherapyACS Medicinal Chemistry Letters · 2025
20. Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization SyndromeACS Medicinal Chemistry Letters · 2025